Primer probe for type 2 diabetes mellitus medication guidance gene detection and application
By using a fluorescent platform combined with ARMS PCR technology and TaqMan-MGB fluorescent probe technology in the personalized drug detection of type 2 diabetes, the problem of insufficient detection sites, long time and complex operation is solved, and the detection site is achieved. Rapid and accurate detection of polymorphisms of type 2 diabetes-related genes, with high sensitivity and low cost.
Patent Information
- Application Number
- CN202411191862.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art has problems in the personalized drug testing of type 2 diabetes, such as insufficient detection sites, long time, complex operation and high equipment requirements, and it is impossible to quickly and accurately perform genetic polymorphism detection.
Using a fluorescence platform combined with ARMS PCR technology and TaqMan-MGB fluorescence probe technology, a primer probe composition including 18 SNP sites is designed to prepare a kit to achieve rapid polymorphisms of type 2 diabetes-related genes Test.
It has achieved rapid and accurate detection of the gene polymorphisms of individualized drug use in type 2 diabetes, with high sensitivity, low cost, simple operation, short detection cycle, low equipment requirements, improved the efficiency of pharmacogenomics research on diabetes.
Smart Images

Figure CN118932046A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of type 2 diabetes medication guidance, and specifically relates to a primer probe for type 2 diabetes medication guidance gene detection and an application thereof. Background Art
[0002] Diabetes is a chronic, non-communicable disease characterized by elevated blood sugar. With the development of social economy, changes in people's diet and lifestyle, and the acceleration of population aging, the prevalence of diabetes has continued to increase worldwide, and it has become one of the most serious public health problems facing countries around the world. In 2021, there were 529 million people with diabetes worldwide, of which the prevalence of type 2 diabetes (T2DM) accounted for more than 80% of the total cases of diabetes. Oral hypoglycemic drugs are a routine choice for the clinical treatment of T2DM, but there are individual differences in their efficacy, and genetics is one of the reasons. Single nucleotide polymorphisms (SNPs) are closely related to pharmacogenetics, leading to differences in blood drug concentrations and drug sensitivity. Therefore, personalized medication based on pharmacogenetics has become one of the important means of treating T2DM.
[0003] At present, domestic and foreign researchers have conducted a lot of research on individualized medication for diabetes and developed a series of detection methods. However, there are still some problems such as insufficient coverage of sites, long detection time, complex operation, and high equipment requirements.
[0004] Patent document CN112795645A discloses a kit for guiding the use of drugs for hyperglycemia in humans, which has 18 detection sites. However, it uses flight mass spectrometry technology, and the equipment is expensive and the operation is complicated.
[0005] Patent document CN112210598A discloses a primer set and a kit for detecting gene polymorphisms related to hyperglycemia drug metabolism and their applications, and detects seven genes. However, it uses Sanger sequencing technology, which has a long detection time and high detection cost.
[0006] CN110157799A discloses a primer probe set, a kit and a method for guiding the detection of gene polymorphisms related to individualized medication for diabetes. It uses fluorescent probe technology to detect five major genes, but has disadvantages such as incomplete detection sites and one well can only detect a single site. Summary of the invention
[0007] In order to solve the problems in the prior art, the present invention provides a primer probe for type 2 diabetes medication guidance gene detection and its application, so as to achieve the purpose of quickly and accurately detecting the gene polymorphism of type 2 diabetes individualized medication.
[0008] The present invention solves the technical problem by adopting the following technical solutions:
[0009] The present invention aims to provide a primer probe for type 2 diabetes medication guidance gene detection, comprising nucleotide sequences SEQ ID NO: 1-SEQ ID NO: 72.
[0010] The invention discloses an application of a primer probe for gene detection for guiding medication of type 2 diabetes in preparing a kit for detecting type 2 diabetes.
[0011] Furthermore, primer probes for type 2 diabetes medication-guided gene testing are used to amplify 18 SNP sites in the preparation kit, and the 18 SNP sites include rs5219, rs1799853, rs1057910, rs757110, rs7903146, rs1801278, rs622342, rs316019, rs8187725, rs2289669, rs12943590, rs11212617, rs8192675, rs1801282, rs11572080, rs4149056, rs2237892 and rs1470579
[0012] Sulfonylureas (SUs) are one of the main oral drugs for the treatment of type 2 diabetes, and commonly used ones include glibenclamide, glimepiride, glipizide, gliclazide, gliquidone, etc. Studies have found that polymorphisms of genes such as ABCC8, KCNJ11, CYP2C9, TCF7L2, and IRS1 are one of the factors leading to individual differences in sulfonylurea treatment.
[0013] Metformin is a basic oral hypoglycemic drug widely used in the treatment of type 2 diabetes. There are significant individual differences in the efficacy and adverse reactions of metformin. About 30% to 40% of patients fail to reduce their blood sugar levels to an ideal level after taking metformin. Studies have found that genetic polymorphisms such as SLC22A1, SLC22A2, SLC22A3, SLC47A1, SLC47A2, ATM, and SLC2A2 are one of the reasons for the individual differences in the therapeutic effect of metformin.
[0014] Thiazolidinediones are insulin sensitizers that promote glucose uptake in tissues and skeletal muscle and downregulate glucose output from the liver. Currently, pioglitazone and rosiglitazone are the main drugs used in clinical practice. The main genes affected are PPARγ, CYP2C8, CYP2C9, etc.
[0015] Meglitinide hypoglycemic drugs are insulin secretagogues that promote insulin secretion by inhibiting KATP channels. Their molecular mechanism is similar to that of sulfonylureas, both of which inhibit the activity of KATP channels by binding to two different SUR1 subunit sites. Meglitinides act more quickly and last for a shorter period of time than sulfonylureas. Their representative drugs are repaglinide and nateglinide. Genetic polymorphisms associated with responsiveness to meglitinide treatment include SLCO1B1, CYP2C8.CYP3A4, TCF7L2, KCNJ11, KCNQ1, IGF2BP2, etc.
[0016] The gene polymorphism sites specifically detected by the kit of the present invention include the rs5219 site of the KCNJ11 gene, the rs1799853 site and the rs1057910 site of the CYP2C9 gene, the rs757110 site of the ABCC8 gene, the rs7903146 site of the TCF7L2 gene, the rs1801278 of the IRS1 gene, the rs622342 site of the SLC22A1 gene, the rs316019 site of the SLC22A2 gene, and the rs8187725 site of the SLC22A3 gene. , rs2289669 site of SLC47A1 gene, rs12943590 site of SLC47A2 gene, rs11212617 site of ATM gene, rs8192675 site of SLC2A2 gene, rs1801282 site of PPARγ gene, rs11572080 site of CYP2C8 gene, rs4149056 site of SLCO1B1 gene, rs2237892 site of KCNQ1 gene, and rs1470579 site of IGF2BP2 gene.
[0017] The specific primer and probe sequences for each detection site are as follows:
[0018]
[0019]
[0020] Among them: WF / WR is the wild-type ARMS primer, MF / MR is the mutant ARMS primer, F / R is the common primer for wild and mutant, and P is the probe.
[0021] Furthermore, the fluorescent group at the 5' end of the probe is a FAM, VIC, HEX, CY5, Texas Red or ROX fluorescent reporter group suitable for fluorescent quantitative PCR analysis, preferably FAM, VIC, ROX, CY5, and the quenching group at the 3' end is a TAMRA, BHQ1, BHQ2, MGB or Dabcy1 fluorescent quenching group suitable for fluorescent quantitative PCR, preferably MGB.
[0022] Furthermore, it also includes PCR reaction solution, primers and probes of internal control genes for monitoring, positive quality control products, and negative quality control products.
[0023] Furthermore, the primers and probes of the internal control gene include nucleotide sequences SEQ ID NO:73-SEQ ID NO:75.
[0024] Furthermore, the PCR reaction solution contains hot-start Taq enzyme, UNG enzyme, buffer, magnesium ions, and dNTP substances required for the PCR reaction.
[0025] Furthermore, the conditions for PCR amplification are as follows: the conditions for UNG enzyme reaction are: 25°C, 10 minutes; the conditions for UNG enzyme inactivation are: 95°C, 2 minutes; the conditions for system amplification are a two-step method: denaturation: 95°C, 5 seconds; annealing extension: 60°C, 30 seconds, setting fluorescence signal collection; the number of cycles is set to 40.
[0026] Furthermore, the wild-type and mutant sequence information of the above 18 sites were used to construct a synthetic sequence gene fragment using a plasmid, and then the fragment was inserted into a T vector, transformed and extracted using the Escherichia coli DH5α strain, and the plasmids were mixed and diluted in equal proportions to obtain a positive quality control product.
[0027] Furthermore, the negative control product is deionized water treated with DEPC.
[0028] The detection sites in the PCR reaction system are shown in the following table.
[0029]
[0030]
[0031] Genotyping interpretation: Under the above PCR reaction system and cycling program conditions, the FAM, VIC, ROX, and CY5 fluorescence detection signals of the two tubes of positive quality control products should form an obvious amplification curve; the FAM, VIC, ROX, and CY5 fluorescence detection signals of the two tubes of negative quality control products should have no obvious amplification curve or the Ct value should be 0.
[0032] When the above conditions are met, observe the amplification curve of the reaction tube of the sample to be tested. If a logarithmic amplification "S"-shaped curve is formed, the sample to be tested contains the corresponding base mutation; if there is no logarithmic amplification "S"-shaped curve or the Ct value is 0, there is no corresponding base mutation.
[0033] Compared with the prior art, the beneficial technical effects of the present invention are:
[0034] (1) The present invention adopts a pre-packaging quadruple reaction system, placing genes related to mainstream diabetes medication guidance in a 12-row eight-tube, reducing the reagent packaging operation in the subsequent detection process, facilitating operation and reducing the possibility of contamination. Currently, there are not many gene detection reagents for safe diabetes medication on the market, which is expected to promote diabetes pharmacogenomic research.
[0035] (2) The present invention is based on a fluorescence platform and uses ARMS PCR technology combined with TaqMan-MGB fluorescent probe technology to provide a kit for guiding gene detection of type 2 diabetes. This kit has the characteristics of high sensitivity, low cost, simple operation, short detection cycle, intuitive interpretation, and low equipment requirements. It can quickly and accurately detect genetic polymorphisms for personalized diabetes medication. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is the amplification curve of the positive quality control product in Example 2 of the present invention.
[0037] Figure 2 This is the amplification curve of the negative control product in Example 2 of the present invention. DETAILED DESCRIPTION
[0038] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments. In addition, unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0039] The inventors screened through literature and found 18 polymorphic sites of genes that are closely related to the efficacy of four major drugs in clinical practice, namely sulfonylurea drugs, metformin, thiazolidinediones drugs, and meglitinides antidiabetic drugs, and prepared a primer-probe combination for detecting the 18 polymorphic sites and a detection kit using the combination, and established an accurate detection method for oral medication for diabetes, thereby achieving effective medication guidance.
[0040] Example 1: Establishment and optimization of detection system
[0041] 1. Arrange the rs5219 site of KCNJ11 gene, the rs1799853 site and rs1057910 site of CYP2C9 gene, the rs757110 site of ABCC8 gene, the rs7903146 site of TCF7L2 gene, the rs1801278 of IRS1 gene, the rs622342 site and rs2289669 site of SLC22A1 gene, the rs316019 site of SLC22A2 gene, the rs8187725 site of SLC22A3 gene, the rs2289669 site of SLC47A1 gene, and the rs2289669 site of SLC47A2 gene. The wild-type and mutant sequences of the rs12943590 site of the gene, the rs11212617 site of the ATM gene, the rs8192675 site of the SLC2A2 gene, the rs1801282 site of the PPARγ gene, the rs11572080 site of the CYP2C8 gene, the rs4149056 site of the SLCO1B1 gene, the rs2237892 site of the KCNQ1 gene, the rs1470579 site of the IGF2BP2 gene, and the internal control GAPDH sequence information were sent to Shanghai Bioengineering to synthesize the wild-type and mutant plasmids and the internal control plasmids. The 37 plasmids were diluted to 10 -4 ng / ul simulated wild-type and mutant samples, and 10 -4 ng / ul simulated wild-type and mutant plasmids were mixed in equal volumes to obtain heterozygous simulated samples.
[0042] 2 Based on the sequence characteristics of the genetic polymorphism sites, design the primers and probes used for sample testing and amplify the analysis results.
[0043] (1) According to the sequence characteristics of the genetic polymorphism sites, the primers and probes used for sample detection are designed to obtain the forward primers, probes, and reverse primers used in the following PCR detection system, including:
[0044] Primer probe sequence for each site
[0045]
[0046]
[0047]
[0048]
[0049]
[0050] Primers and probes for detecting the internal control gene GAPDH:
[0051] GAPDH-F: CTAGGGACGGCCTGAAGG
[0052] GAPDH-R:CGCCGCATCACGTCCTC
[0053] GAPDH-P: CY5-CAGGGGCGGGCGCAGG-MGB
[0054] (2) Screening was performed on each site primer probe, with one tube for the wild-type system and one tube for the mutant system. The detection systems are shown in Tables 1 and 2.
[0055] Table 1: Wild-type single-plex detection system
[0056]
[0057]
[0058] Table 2: Mutation-type single-plex detection system
[0059] Reagent name Volume (μL) TaKaRa Taq HS (5U / μL) 0.15 10×PCR Buffer (Mg2+plus) 2.5 dU plus dNTP Mixture (12.5X) 4ul UNG (2U / μL) 0.1 Mutation Primer 0.5 Universal primer 0.5 Probe 0.3 DNA (template) 2 DEPC water Make up to 25ul
[0060] The DNA templates are the wild-type and mutant simulation samples synthesized and diluted in step 1, and the primers and probes are the primers and probes shown in step 2 (1).
[0061] Universal primers and probes were fixed in each single-plex PCR mutant detection system, and one mutant ARMS primer was added each time; universal primers or probes were fixed in each single-plex PCR wild-type detection system, and one wild-type ARMS primer was added each time until all primer and probe combinations in step 2 obtained detection results, thereby screening wild-type and mutant primers and probes. In each single-plex PCR mutant detection system and single-plex PCR wild-type detection system, the DNA samples added were the corresponding wild-type and mutant plasmids, respectively, with a final concentration of 10 -4 ng / ul.
[0062] (3) The prepared single-plex PCR wild-type detection system and single-plex PCR mutant detection system are subjected to PCR amplification. The PCR reaction procedure is as follows:
[0063] Stage 1: 25°C, 10 minutes;
[0064] Second stage: 95℃, 2 minutes;
[0065] The third stage: 95°C, 5 seconds; 58°C, 30 seconds, the number of cycles is set to 40; fluorescence is collected at 58°C.
[0066] (4) Experimental results: Single-plex PCR was performed on the above primers and probes, and the CT values of the single-plex PCR wild-type detection system and the single-plex PCR mutant detection system were directly read. According to the CT results, firstly, primers with a CT value of 22-30 for the wild-type detection system and no CT value or greater than 37 for the mutant plasmid were selected, and primers with a CT value of 22-30 for the mutant plasmid and no CT value or greater than 37 for the mutant detection system were selected. Then, primers with a CT value difference of 2 between the wild-type primer and the mutant primer were selected. The primer-probe combination finally selected is shown in the following table:
[0067]
[0068]
[0069] 3 Based on the specific probe screened by single-plex PCR, add internal control to prepare the wild-type tube PCR reaction solution and mutant tube PCR reaction solution respectively, and adjust the amount of primers and probes at each site, as well as different combinations of each site, so that the CT value and signal value of each site are closer. The final reaction system is as follows:
[0070] PCR reaction solution 1:
[0071]
[0072]
[0073] PCR reaction solution 2:
[0074] Reagent name Volume (μL) TaKaRa Taq HS (5U / μL) 0.15 10×PCR Buffer (Mg2+plus) 2.5 dU plus dNTP Mixture (12.5X) 4ul UNG (2U / μL) 0.1 5219-P 0.5 5219-R 0.5 5219-MF2 1 9853-P 1 9853-R 1 9853-MF4 1 7910-P 0.4 7910-R 0.6 7910-MF4 0.6 GAPDH-F 0.2 GAPDH-R 0.2 GAPDH-P 0.2 DNA (template) 2 DEPC water Make up to 25ul
[0075] PCR reaction solution 3:
[0076]
[0077]
[0078] PCR reaction solution 4:
[0079] Reagent name Volume (μL) TaKaRa Taq HS (5U / μL) 0.15 10×PCR Buffer (Mg2+plus) 2.5 dU plus dNTP Mixture (12.5X) 4ul UNG (2U / μL) 0.1 7110-MF3 0.5 7110-R 0.5 7110-P 0.3 3146-MR2 0.5 3146-F 0.5 3146-P 0.3 1278-MF2 0.6 1278-R 0.6 1278-P 0.3 GAPDH-F 0.2 GAPDH-R 0.2 GAPDH-P 0.2 DNA (template) 2 DEPC water Make up to 25ul
[0080] PCR reaction solution 5:
[0081]
[0082]
[0083] PCR reaction solution 6:
[0084] Reagent name Volume (μL) TaKaRa Taq HS (5U / μL) 0.15 10×PCR Buffer (Mg2+plus) 2.5 dU plus dNTP Mixture (12.5X) 4ul UNG (2U / μL) 0.1 2342-MF3 1 2342-R 1 2342-P 0.5 6019-MF3 0.6 6019-R 0.6 6019-P 0.3 7725-MF4 0.5 7725-R 0.5 7725-P 0.3 GAPDH-F 0.2 GAPDH-R 0.2 GAPDH-P 0.2 DNA (template) 2 DEPC water Make up to 25ul
[0085] PCR reaction solution 7:
[0086]
[0087]
[0088] PCR reaction solution 8:
[0089] Reagent name Volume (μL) TaKaRa Taq HS (5U / μL) 0.15 10×PCR Buffer (Mg2+plus) 2.5 dU plus dNTP Mixture (12.5X) 4ul UNG (2U / μL) 0.1 9669-MF3 0.8 9669-R 0.8 9669-P 0.4 3590-MF3 0.6 3590-R 0.6 3590-P 0.3 2617-MF3 0.6 2617-R 0.6 2617-P 0.3 GAPDH-F 0.2 GAPDH-R 0.2 GAPDH-P 0.2 DNA (template) 2 DEPC water Make up to 25ul
[0090] PCR reaction solution 9:
[0091]
[0092]
[0093] PCR reaction solution 10:
[0094] Reagent name Volume (μL) TaKaRa Taq HS (5U / μL) 0.15 10×PCR Buffer (Mg2+plus) 2.5 dU plus dNTP Mixture (12.5X) 4ul UNG (2U / μL) 0.1 2675-MR4 0.5 2675-F 0.5 2675-P 0.3 1282-MF3 0.6 1282-R 0.6 1282-P 0.3 2080-MF3 0.5 2080-R 0.5 2080-P 0.3 GAPDH-F 0.2 GAPDH-R 0.2 GAPDH-P 0.2 DNA (template) 2 DEPC water Make up to 25ul
[0095] PCR reaction solution 11:
[0096]
[0097]
[0098] PCR reaction solution 12:
[0099] Reagent name Volume (μL) TaKaRa Taq HS (5U / μL) 0.15 10×PCR Buffer (Mg2+plus) 2.5 dU plus dNTP Mixture (12.5X) 4ul UNG (2U / μL) 0.1 9056-MR4 0.8 9056-F 0.8 9056-P 0.4 7892-MF3 1 7892-R 1 7892-P 0.6 0579-MF3 0.5 0579-R 0.5 0579-P 0.3 GAPDH-F 0.2 GAPDH-R 0.2 GAPDH-P 0.2 DNA (template) 2 DEPC water Make up to 25ul
[0100] The above primers and probes can be used to specifically detect the types of diabetes medication-related gene mutations in samples, as shown in the following table:
[0101]
[0102]
[0103] 5 Design of the kit: The kit of the present invention comprises 12 tubes of PCR reaction solution, which are pre-packed in PCR12 strip tubes, indicating the rs5219 site of KCNJ11 gene, the rs1799853 site and rs1057910 site of CYP2C9 gene, the rs757110 site of ABCC8 gene, the rs7903146 site of TCF7L2 gene, the rs1801278 of IRS1 gene, the rs622342 site and rs2289669 site of SLC22A1 gene, the rs316019 site of SLC22A2 gene, the rs8187725 site of SLC47A3 gene, and the rs1799853 site and rs1057910 site of CYP2C9 gene, respectively. The rs2289669 site of the A1 gene, the rs12943590 site of the SLC47A2 gene, the rs11212617 site of the ATM gene, the rs8192675 site of the SLC2A2 gene, the rs1801282 site of the PPARγ gene, the rs11572080 site of the CYP2C8 gene, the rs4149056 site of the SLCO1B1 gene, the rs2237892 site of the KCNQ1 gene, and the different genotypes of the rs1470579 site of the IGF2BP2 gene. Negative quality control products are used to indicate whether the test is contaminated, and positive quality control products are used to monitor whether the entire process reacts normally.
[0104] 6. Obtaining positive quality control products
[0105] The rs5219 site of KCNJ11 gene, the rs1799853 site and rs1057910 site of CYP2C9 gene, the rs757110 site of ABCC8 gene, the rs7903146 site of TCF7L2 gene, the rs1801278 of IRS1 gene, the rs622342 site and rs2289669 site of SLC22A1 gene, the rs316019 site of SLC22A2 gene, the rs8187725 site of SLC22A3 gene, the rs2289669 site of SLC47A1 gene, and the rs2289669 site of SLC4 The rs12943590 site of the 7A2 gene, the rs11212617 site of the ATM gene, the rs8192675 site of the SLC2A2 gene, the rs1801282 site of the PPARγ gene, the rs11572080 site of the CYP2C8 gene, the rs4149056 site of the SLCO1B1 gene, the rs2237892 site of the KCNQ1 gene, the rs1470579 site of the IGF2BP2 gene and the sequence information of GAPDH were sent to Shanghai Bio-Tech for synthesis of wild-type, mutant and internal control plasmids. The 37 plasmids were mixed in equal amounts and diluted to 10 -4 ng / ul to obtain positive quality control.
[0106] Example 2: Use of Gene Detection Kit
[0107] 1. Sample collection and processing
[0108] Peripheral blood was collected from patients using a vacuum tube containing EDTA anticoagulant to collect 5 ml of blood specimens. Nucleic acids were extracted using the acid extraction kit (magnetic bead method) produced by Chongqing Puji. The experimental steps were carried out according to the instructions.
[0109] 2. Preparation of reaction system
[0110] The reaction system was prepared according to the PCR reaction solutions 1-12 in Example 1 and pre-packed in PCR 12 tube strips.
[0111] 3. PCR reaction
[0112] Add the DNA extracted from the sample to the aliquoted reaction system, and add 1-200ng of template. When performing PCR reaction, the sample to be tested, the positive quality control product and the negative quality control product need to be tested in parallel on the machine, and each sample needs to be added to 1-12 reaction tubes at the same time.
[0113] 4. Instrument channel and reaction volume selection
[0114] ① Select FAM channel (Reporter: FAM, Quencher: MGB), VIC channel (Reporter: VIC, Quencher: MGB), ROX channel (Reporter: ROX, Quencher: MGB) and CY5 channel (Reporter: CY5, Quencher: MGB) to detect amplification.
[0115] ②The reaction volume (Sample Volume) is 25μL.
[0116] ③ Reference Dye: If you are using an ABI series PCR instrument, please be sure to select "none" in the passive reference; for specific detection channel settings, please refer to the instructions for use of each instrument.
[0117] Stage 1: 25°C, 10 minutes;
[0118] Second stage: 95℃, 2 minutes;
[0119] The third stage: 95°C, 5 seconds; 58°C, 30 seconds, the number of cycles is set to 40; fluorescence is collected at 58°C.
[0120] 6. Experimental results
[0121] After the reaction program is completed, the results are saved and interpreted. If the amplification Ct value is ≤35, it is detected; otherwise, it is judged as not detected.
[0122] The FAM, VIC, ROX, and CY5 fluorescence detection signals in the positive control tubes 1-12 form a logarithmic amplification "S" curve (see Appendix Figure 1 ); negative control product 1-12 reaction tubes have no amplification curve (see attached Figure 2 ).
[0123] Example 3: Determination of the genotype determination criteria of the kit
[0124] According to the detection method in Example 2, the CT value of the PCR detection system is directly read, and the genotype is judged according to the CT values of the wild-type system and the mutant system of the PCR detection system. Based on the detection results of this kit and the first-generation sequencing of 120 human peripheral blood gDNA samples, according to the ROC curve, the calculated positive judgment value result is 35, the wild-type system CT value ≤35, the mutant system CT value>35 is wild type; the mutant system CT value ≤35, the wild-type system CT value>35 is mutant; the wild-type and mutant system CT values are both less than 35 for heterozygous.
[0125] Example 4: Accurate performance evaluation of the kit
[0126] 10 clinical samples were selected and tested according to the test method of Example 2 and the judgment criteria of Example 3, and the gold standard Sanger sequencing method was used for accuracy comparison. The test results are as follows:
[0127] Accuracy test results
[0128]
[0129]
[0130] The detection results of each sample in the accuracy test results are consistent with the comparison results, indicating that the detection system of the kit of Example 2 has good accuracy.
[0131] Example 5: Detection limit performance evaluation of the kit
[0132] Select three detection limit reference products L1, L2, L3, dilute them with TE buffer to 10ng / μL, 5ng / μL, 2.5ng / μL and 1ng / μL, 0.5g / μL, and perform detection according to the method of Example 2 and the judgment standard of Example 3. Repeat the detection 20 times for each concentration reference product. The results are shown in the following table:
[0133] Detection limit test results
[0134]
[0135] The detection limit of the kit of the present invention is calculated to be as low as 1 ng / μL using a detection rate of 95% as the minimum detection limit, and the invention has good sensitivity.
[0136] Example 6: Evaluation of Kit Precision
[0137] Two precision reference products J1 (plasmids mixed to make all sites heterozygous) and J2 (J2 is a clinical sample) were selected for testing according to the method of Example 2, with two batches per day, and each batch was tested 4 times for 5 days. The coefficient of variation (CV, %) was calculated using the Ct values of the 40 test results of the precision experiment. The results are shown in the following table:
[0138]
[0139]
[0140] The calculation results showed that the intra-batch and inter-batch precision results were both within 5%, indicating that the kit of the present invention has good repeatability.
[0141] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative rather than restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.
Claims
1. A primer probe for type 2 diabetes medication guidance gene detection, characterized in that: Including nucleotide sequences SEQ ID NO: 1-SEQ ID NO:
72.
2. Use of a primer probe for drug-guided gene detection of type 2 diabetes as claimed in claim 1 in the preparation of a kit for detecting type 2 diabetes.
3. The kit for detecting type 2 diabetes as claimed in claim 2, characterized in that: The primer probes for type 2 diabetes medication-guided gene testing are used to amplify 18 SNP sites in the preparation kit. The 18 SNP sites include rs5219, rs1799853, rs1057910, rs757110, rs7903146, rs1801278, rs622342, rs316019, rs8187725, rs2289669, rs12943590, rs11212617, rs8192675, rs1801282, rs11572080, rs4149056, rs2237892 and rs1470579 4. The kit for detecting type 2 diabetes as claimed in claim 3, characterized in that: It also includes PCR reaction solution and primers and probes for internal control genes used for monitoring.
5. The kit for detecting type 2 diabetes as claimed in claim 4, characterized in that: The primers and probes for the internal control gene include nucleotide sequences SEQ ID NO:73-SEQ ID NO:
75.
6. The kit for detecting type 2 diabetes as claimed in claim 4, characterized in that: The PCR reaction solution contains the hot-start Taq enzyme, UNG enzyme, buffer, magnesium ions, and dNTP substances required for the PCR reaction.
7. The kit for detecting type 2 diabetes as claimed in claim 6, characterized in that: The conditions for PCR amplification were as follows: the conditions for UNG enzyme reaction were as follows: 25°C, 10 min; The conditions for UNG enzyme inactivation were: 95°C, 2 min; The amplification conditions of the system are a two-step method: denaturation: 95°C, 5 seconds; annealing extension: 60°C, 30 seconds, set fluorescence signal collection; the number of cycles is set to 40.
